drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cell therapy (CAR-T)
drug_description
Autologous gene-modified T cells engineered to express an anti-CD19 chimeric antigen receptor, enabling targeted depletion of CD19+ B cells to reduce autoantibody production and reset dysregulated humoral immunity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express an anti-CD19 chimeric antigen receptor that recognizes CD19 on B cells and triggers T-cell activation and cytotoxic killing, depleting CD19+ B-cell subsets to reduce autoantibody production and B cell–mediated antigen presentation, thereby resetting dysregulated humoral immunity.
drug_name
CD19 CAR-T cells
nct_id_drug_ref
NCT06688799